Egle was spun out of Institut Curie, and has developed a proprietary target discovery engine that uses patient samples to map unique transcriptomic signatures at single-cell resolution. The system will help identify targets for specific tumor-infiltrating Treg subpopulations.

The company is building a Treg-modulating drug pipeline that also includes resurfaced interleukin-2 (IL-2) proprietary variants with unique mechanisms of action to engage or disengage Tregs.

Under the agreement, Egle will lead target validation efforts on a subset of targets and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle will receive an upfront payment and research funding and will be eligible to receive additional development and sales milestone payments.

Additionally, Takeda will invest $5.2 million in convertible debt through its venture arm to support Egle's corporate growth and internal IL-2-based Treg modulation programs.